New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 21, 2014
08:58 EDTACT, IPXLImpax appoints G. Frederick Wilkinson as CEOActavis
Impax Laboratories (IPXL) has appointed G. Frederick Wilkinson as Impax's president and CEO effective April 29. Mr. Wilkinson, who previously served as President, Actavis Global Research and Development at Actavis (ACT), succeeds Larry Hsu, Ph.D. who is retiring.
News For IPXL;ACT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
November 14, 2014
12:53 EDTACTOmega Advisors gives quarterly update on stakes
NEW STAKES: AerCap Holdings (AER), Nordic American Offshore (NAO), Melco Crown Entertainment (MPEL), Groupon (GRPN), and Ashland (ASH). INCREASED STAKES: QEP Resources (QEP), United Continental (UAL), Cabot Oil & Gas (COG), Actavis (ACT), and KAR Auction Services (KAR). DECREASED STAKES: Sprint (S), SandRidge Energy (SD), Sirius XM Holdings (SIRI), Kinder Morgan (KMI), and Transocean (RIG). LIQUIDATED STAKES: QUALCOMM (QCOM), Ocwen Financial (OCN), Freeport-McMoRan (FCX), Boston Scientific (BSX), and Capital One (COF).
07:32 EDTACTHayman Capital gives quarterly update on stakes
Subscribe for More Information
November 13, 2014
10:44 EDTACTMallinckrodt news on generic Concerta positive for Actavis, says BMO Capital
Subscribe for More Information
08:15 EDTACTActavis' sNDA for bipolar disorder candidate Saphris accepted by FDA
Subscribe for More Information
07:23 EDTACTValeant wooing doctors ahead of hoped for Allergan acquisition, WSJ says
Subscribe for More Information
November 12, 2014
10:09 EDTACTActavis in talks to buy Allergan for over $200 per share, Bloomberg says
Subscribe for More Information
10:01 EDTACTActavis in talks to buy Allergan for $60B, more than $200/share Bloomberg says
Actavis (ACT) is said to seek to pay about $200 per share, but Allergan (AGN) seeks about $210 per share, according to Bloomberg.
November 11, 2014
08:32 EDTACTValeant likely to raise offer for Allergan again, says Bernstein
Subscribe for More Information
November 10, 2014
16:34 EDTACTActavis appoints Maria Teresa Hilado as CFO
Subscribe for More Information
November 7, 2014
09:49 EDTACTAckman says Allergan 'tipping scales' in Actavis’ favor, disadvantaging Valeant
Subscribe for More Information
08:21 EDTIPXLImpax discloses receipt of subpoena from DOJ regarding generics
Impax (IPXL) disclosed in a regulatory filing that on November 3 a sales representative of Impax Laboratories received a subpoena from the Justice Department’s Antitrust Division requesting the production of documents to and testimony before the grand jury of the Eastern District of Pennsylvania. The request relates to any communication or correspondence with any competitor, or an employee of any competitor, in the sale of generic prescription medications, Impax said. The Fly notes Lannett (LCI) disclosed yesterday in a similar filing that on that same date its Senior Vice President of Sales and Marketing was served with a grand jury subpoena relating to a federal investigation of the generic pharmaceutical industry into possible violations of the Sherman Act.
November 6, 2014
10:30 EDTACTAllergan disclosure today forced by SEC, CNBC's Faber reports
Subscribe for More Information
10:05 EDTACTActavis talks to buy Salix put on hold, Bloomberg says
Subscribe for More Information
09:28 EDTACTActavis in active talks to acquire Allergan, Bloomberg reports
Actavis (ACT) is in active talks to acquire Allergan (AGN), Bloomberg reports, citing sources. Allergan earlier today disclosed in a filing that it has been approached by another party and that talks "may lead to negotiations." Shares of Allergan are up 1.1% to $198.50 in pre-open trading while Actavis is up 1% to $250.07. Valeant (VRX) is down 1.8% to $129.58. Reference Link
09:24 EDTACTActavis in active talks to acquire Allergan, Bloomberg reports
Subscribe for More Information
09:22 EDTACTActavis price target raised to $290 from $270 at Susquehanna
Subscribe for More Information
09:06 EDTACTAllergan says approach may lead to merger negotiations
Allergan (AGN) disclosed in new regulatory filing, “Notwithstanding the foregoing, we have been approached by another party regarding a potential merger transaction. Discussions between us and that party have continued and may lead to negotiations.” It has been reported that the unnamed party is Actavis (ACT). Allergan is attempting to fend off a hostile takeover by Valeant (VRX).
07:54 EDTACTActavis pipeline remains under-appreciated, says UBS
Subscribe for More Information
07:52 EDTACTActavis price target raised to $290 from $260 at Leerink
Subscribe for More Information
07:40 EDTIPXLImpax submits marketing authorization application to EMA for IPX066
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use